On May 16, 2025, Qingdao Baheal Pharma Co., Ltd, a subsidiary of Baheal Pharma under Baheal Medical (301015.SZ), held a relocation ceremony to celebrate its Phase III construction project. Mr. Zhu Xiaowei, Director of Baheal Pharma Group, Vice President of Baheal Medical and Chairman of Baheal Pharma, Mr. Hao Yu, Vice President of Baheal Pharma Group's Campus Operation, Ms. Zheng Aiju, General Manager of Qingdao Baheal Pharma, and other leaders and guests, as well as colleagues of Qingdao Baheal Pharma, were present at the ceremony to witness this important moment together.

On February 22, 2025, the "China Intracranial Metastases Consortium" (CLAIM) held its founding meeting and the first Xuanwu Intracranial Metastases Forum in Beijing. The event brought together nearly 170 experts and scholars from 108 hospitals, spanning oncology, radiotherapy, neurosurgery, pathology, and imaging departments, to discuss multidisciplinary approaches to treating intracranial metastases, intending to enhance patient survival.

On November 25, 2024, BrioHealth Solutions, Inc., a wholly-owned BrioHealth's U.S. subsidiary, announced its independently developed fully magnetic levitation left ventricular assist device, BrioVAD®, had successful completed the first patient enrollment of the INNOVATE clinical trial at Emory University Hospital.

On November 25, 2024, Qingdao Baheal Medical Co., Ltd. (301015.SZ, hereinafter referred to as "Baheal Medical") announced that it has entered an exclusive commercialization partnership with ZAP Surgical Systems, Inc. (hereinafter referred to as "ZAP"), a global leader in radiosurgical robots. This agreement grants Baheal Medical the rights to commercialize ZAP-X® Gyroscopic Radiosurgery Platform and its related accessories in mainland China, Hong Kong, and Macau. This profound collaboration marks Baheal Medical's official entry into the precision radiotherapy market, promoting the clinical application of the world’s first self-shielding radiotherapy device.

November 14, 2024 — Qingdao Baheal Medical INC. (“Baheal Medical”, stock code: 301015.SZ) announced that its wholly-owned subsidiary, Beijing Baheal ZHIHE Medical Achievement Transformation Service Co., Ltd., has signed a marketing cooperation agreement with Beijing Biostar Biopharmaceutical Co., Ltd. (“Biostar”, stock code: 2563.HK). Under the agreement, Baheal Medical will obtain exclusive marketing rights in mainland China for Biostar’s independently developed Class 1 innovative drug, Utidelone Injection (brand name: UTIDE®). Baheal Medical will make a non-refundable upfront payment of RMB 50 million to Biostar, and additional milestone payments based on development and sales progress. In return, Biostar will pay Baheal Pharma a tiered promotion service fee based on annual terminal sales.